We're an experienced and talented group of entrepreneurs and scientists with a groundbreaking idea that we hope will be better tomorrow.
|주요사업||비소세포폐암 (NSCLC) 표적항암제 (AGK-102: 항TM4SF4 단일클론항체)
백금계저항성 난소암 적용 엽산수용체알파(Folate Receptor alpha, FRα) 표적항암제 (Idetrexed(이데트렉세드)
|소재지||320 120th Ave. NE, Suite 208 Bellevue, WA 98005, USA|
· Invented by Korea Atomic Energy Research Institute in Korea
· Algok obtained an exclusive global right for all uses of novel TM4SF4 monoclonal antibody for cancer therapeutics
· Sponsored research is planned for 3 years
· TM4SM4 as a novel cancer stem cell biomarker related to resistance of radiotherapy
· Anti-TM4SM4 treatment suppresses tumors by down-regulation of OPN and blocking IGF1R signaling
· NSCLC, pancreatic, liver, blood cancer expressing TM4SM4
· Initiation of preclinical development in 2H 2022
· 3 PCT filed including the composition of matter of novel antibody sequences
· 2 Published in OncoTarget in 2015 and 2017
CSC is characterized by self‐renewal, metastasis, apoptosis, heterogeneity, immune resistance, and radio/chemo resistance.
TM4SF4 is highly expressed in radio-resistant lung adenocarcinoma cells.
Tumorigenic activity of TM4SF4 in lung adenocarcinoma xenograft was completely suppressed by anti-TM4SF4 antibody treatment.